K

    KZR (KZR)

    Official site

    BIOTECHNOLOGY

    $7.29
    +0.00 (+0.00%)

    Last updated: May 11, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(22/32)
    Avg Surprise
    -42.36%
    Streak
    2 Q

    Upcoming Estimates

    Jun 30, 2026
    EPS Consensus$-0.91
    Range$-0.91 - $-0.91
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-1.25-37.9%
    60d ago$-1.25-37.9%
    30d ago$-1.25-37.9%
    7d ago$-0.91+0.0%
    Current$-0.91
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Sep 30, 2026
    EPS Consensus$-0.87
    Range$-0.87 - $-0.87
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-1.24-42.0%
    60d ago$-1.24-42.0%
    30d ago$-1.24-42.0%
    7d ago$-0.87+0.0%
    Current$-0.87
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.26---
    Sep 26EST
    		-$-0.87---
    Jun 26EST
    		-$-0.91---
    Mar 26
    		$-0.70$-0.98+28.53%Beat+65.0%
    Dec 25
    		$-1.05$-1.31+19.57%Beat+64.9%
    Sep 25
    		$-1.53$-0.26-488.46%Miss+45.0%
    Jun 25
    		$-1.87$-0.28-567.86%Miss-592.6%
    Mar 25
    		$-2.00$-2.65+24.53%Beat-566.7%
    Dec 24
    		$-3.00$-2.76-8.70%Miss-581.8%
    Sep 24
    		$-2.78$-3.15+11.75%Beat-768.8%
    Jun 24
    		$-0.27$-0.32+15.63%Beat+20.6%
    Mar 24
    		$-0.30$-0.33+9.09%Beat+3.2%
    Dec 23
    		$-0.44$-0.38-15.79%Miss-76.0%
    Sep 23
    		$-0.32$-0.35+8.57%Beat-28.0%
    Jun 23
    		$-0.34$-0.32-6.25%Miss-36.0%
    Mar 23
    		$-0.31$-0.29-6.90%Miss-19.2%
    Dec 22
    		$-0.25$-0.28+10.71%Beat+0.0%
    Sep 22
    		$-0.25$-0.27+7.41%Beat+10.7%
    Jun 22
    		$-0.25$-0.27+7.41%Beat+0.0%
    Mar 22
    		$-0.26$-0.28+7.14%Beat-4.0%
    Dec 21
    		$-0.25$-0.30+16.67%Beat-13.6%
    Sep 21
    		$-0.28$-0.26-7.69%Miss-21.7%
    Jun 21
    		$-0.25$-0.26+3.85%Beat-13.6%
    Mar 21
    		$-0.25$-0.24-4.17%Miss+16.7%
    Dec 20
    		$-0.22$-0.23+4.35%Beat+56.0%
    Sep 20
    		$-0.23$-0.21-9.52%Miss+52.1%
    Jun 20
    		$-0.22$-0.26+15.38%Beat+52.2%
    Mar 20
    		$-0.30$-0.37+18.92%Beat+25.0%
    Dec 19
    		$-0.50$-0.54+7.41%Beat-66.7%
    Sep 19
    		$-0.48$-0.51+5.88%Beat-60.0%
    Jun 19
    		$-0.46$-0.48+4.17%Beat+86.1%
    Mar 19
    		$-0.40$-0.40+0.00%Beat+91.4%
    Dec 18
    		$-0.30$-0.44+31.82%Beat-1600.0%
    Sep 18
    		$-0.30$-0.48+37.50%Beat-
    Jun 18
    		$-3.31$-0.52-536.54%Miss-
    Mar 18
    		$-4.67$0.00N/AMiss-
    Dec 17
    		$0.02$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.33
    SMA 20$7.32
    SMA 50$7.13
    SMA 200$5.81
    EMA 10$7.32
    EMA 20$7.30
    EMA 50$7.10
    EMA 200$6.21

    MACD

    Line: 0.06Signal: 0.08Hist: -0.02

    ADX

    ADX: 29.3+DI: 23.0-DI: 14.4

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down40.0
    PSAR$6.73

    Bollinger Bands

    Upper Band$7.40
    Lower Band$7.25
    %B Position206%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    52.5

    Momentum Oscillators

    Stoch %K37.5
    Stoch %D49.7
    Williams %R-75.0
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)-88.9
    MFI (14d)36.4

    Volatility Measures

    ATR (14d)$0.13(1.8%)
    StdDev (20d)0.04
    Hist Vol8.3%(Low)

    Volume Flow

    VWAP$7.29
    OBV3.6M
    AD Line3.2M
    CMF (20d)-0.428

    Volume Metrics

    Avg Vol (20d)125.2K
    Vol RatioN/A
    VWMA (20d)$7.33

    Pivot Points

    R3$7.62
    R2$7.54
    R1$7.42
    Pivot Point$7.34
    S1$7.22
    S2$7.14
    S3$7.02

    Advanced Oscillators

    TSI14.14
    Ultimate Osc41.9
    KST33.35

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$0$0$0$0$0$1.04M$0$0$0$-5,428,000$7.00M$0
    Cost of Revenue$0$176,000$0$0$0$259,000$0$0$0$280,000$0$0
    Gross Profit$0$-176,000$0$0$0$521,000$0$0$0$-280,000$7.00M$0
    Operating Expenses$7.37M$15.16M$11.71M$14.60M$17.63M$21.56M$21.95M$23.38M$23.71M$34.59M$32.53M$26.78M
    R&D$1.54M$5.08M$6.91M$9.58M$12.18M$16.03M$16.24M$16.30M$17.17M$22.64M$23.74M$21.00M
    SG&A$5.21M$2.71M$5.34M$5.02M$5.45M$5.14M$6.11M$5.60M$6.54M$5.76M$8.79M$5.79M
    Operating Income$-7,365,000$-15,164,000$-11,715,000$-14,599,000$-17,629,000$-21,563,000$-21,948,000$-23,383,000$-23,711,000$-34,589,000$-25,527,000$-26,784,000
    Interest Income$609,000$801,000$1.03M$1.20M$1.42M$1.73M$2.04M$2.24M$2.45M$2.73M$2.82M$2.86M
    Interest Expense$0$0$0$302,000$347,000$0$0$401,000$400,000$0$396,000$385,000
    Income Before Tax$-5,756,000$-14,546,000$-11,227,000$-13,704,000$-16,556,000$-20,218,000$-20,313,000$-21,547,000$-21,658,000$-32,260,000$-23,103,000$-24,308,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-5,756,000$-14,546,000$-11,227,000$-13,704,000$-16,556,000$-20,218,000$-20,313,000$-21,547,000$-21,658,000$-32,260,000$-23,103,000$-24,308,000
    EBITDA$-6,318,000$-15,283,000$-11,945,000$-14,901,000$-17,907,000$-22,153,000$-22,850,000$-24,446,000$-24,900,000$-35,782,000$-26,957,000$-28,295,000
    EBIT$-6,365,000$-15,164,000$-11,715,000$-14,599,000$-17,629,000$-21,563,000$-21,948,000$-23,383,000$-23,711,000$-34,589,000$-25,527,000$-26,784,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KZR

    News

    Articles from Enodia Therapeutics and Kezar Life Sciences, Inc.

    Enodia Therapeutics has acquired preclinical assets from Kezar Life Sciences' Sec61-based discovery and development program. This acquisition will strengthen Enodia's Sec61 portfolio by enhancing its understanding of selectivity mechanisms, thereby accelerating its progress towards clinical milestones. Kezar Life Sciences (Nasdaq: KZR) is a clinical-stage biotechnology company focused on immune-mediated diseases.

    FinancialContent•8/1/26•
    Somewhat-Bullish

    Kezar Life Sciences updates its autoimmune pipeline as investors assess long-term prospects

    Kezar Life Sciences (KZR) is a clinical-stage biotechnology company focused on developing targeted therapies for autoimmune diseases. The company's strategy involves advancing a pipeline of drug candidates designed to modulate the immune system with greater precision, while also focusing on obtaining external capital through equity offerings and collaborations. Investors are closely monitoring the company's clinical progress, funding position, and regulatory pathways to assess its long-term prospects in the competitive biotech landscape.

    Ad-hoc-news.de•7/3/26•
    Somewhat-Bullish

    Kezar Life Sciences updates drug pipeline, shares trade on Nasdaq

    Kezar Life Sciences, a clinical-stage biotechnology company, has provided an update on its autoimmune and oncology drug pipeline. The company is primarily focused on its lead candidate, zetomipzomib, a selective immunoproteasome inhibitor in Phase 2 studies for autoimmune diseases like lupus nephritis. Kezar Life Sciences shares trade on Nasdaq under the ticker KZR.

    Ad-hoc-news.de•6/25/26•
    Somewhat-Bullish

    Kezar Life Sciences (KZR) Proxy Filing Summary

    Kezar Life Sciences (KZR) has released its proxy filing summary for the 2025 Annual Meeting, scheduled for June 17, 2025. Shareholders will vote on the election of three directors, an advisory say-on-pay, and the ratification of KPMG LLP as the auditor. The board, consisting of eight members with a majority independent, recommends voting in favor of all proposals, and a one-for-ten reverse stock split was effected in October 2024.

    Quartr•6/19/26•
    Neutral

    Kezar Life Sciences Inc (KZR) Earnings Forecast: Future EPS & Revenue Growth Estimates

    Kezar Life Sciences Inc (KZR) has an earnings forecast score of 6.40, placing it 332nd out of 384 companies in the Biotechnology & Medical Research industry. Analysts have set an average price target of $6.00 for KZR. The company's previous quarter's EPS was -$1.99, significantly missing the market expectation of -$0.78, with the next quarter's EPS expected to be -$0.88.

    TradingKey•6/18/26•
    Neutral

    Frequently Asked Questions About KZR

    Does KZR pay dividends?
    KZR (KZR) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In